NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SentinelOne, Inc. (NYSE: S) between June 1, 2022 and June 1, 2023, both dates inclusive (the “Class Period”), of the important August 7, 2023 lead plaintiff deadline. SO WHAT: If you purchased SentinelOne securities during the […]

Read More

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the “Class Period”), of the important September 12, 2023 lead plaintiff deadline. SO WHAT: If you […]

Read More

WASHINGTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Today, EB5 Capital announced that investors in its Columbia Place (JF9) project have started receiving I-829 approvals from the United States Citizenship and Immigration Services (USCIS). These approvals signify the investors’ eligibility for permanent residency, as they demonstrate the successful creation of at least ten full-time jobs for […]

Read More

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Party City Holdco Inc. (NYSE: PRTY) (OTC: PRTYQ) between November 8, 2022 and June 9, 2023, both dates inclusive (the “Class Period”). […]

Read More

ABU DHABI, United Arab Emirates, Aug. 03, 2023 (GLOBE NEWSWIRE) — Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has established two new departments and four associated graduate programs dedicated to robotics and computer science, catering to the surging global demand for these disciplines, which is expected to hit USD $225 billioni and $140 billion, respectively, […]

Read More

L’étude a montré que l’obéxélimab produisait une amélioration clinique rapide, forte et soutenue, y compris une rémission clinique complète, chez la plupart des patients atteints de ML-IgG4 active Les résultats soutiennent la poursuite du développement de l’obéxélimab pour le traitement de la ML-IgG4 et potentiellement d’autres maladies auto-immunes à médiation par les cellules B WALTHAM, […]

Read More

Estudo revelou que o obexelimabe produziu melhora clínica rápida, forte e sustentada, incluindo remissão clínica completa, na maioria dos pacientes com IgG4-RD ativa Os resultados apoiam o desenvolvimento contínuo do obexelimabe para o tratamento de IgG4-RD e potencialmente outras condições autoimunes mediadas por células B WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) — A Zenas […]

Read More